QNRX: Targeting Completing Recruitment for NS Trial by YE26
In addition to treatment of NS, QRX003 is also being evaluated for pediatric NS and Peeling Skin Syndrome (PSS). Quoin has also advanced its...
88 Views
QNRX: Preparing to Commercialize Lead Asset Through Global Sales Infrastructure
QNRX has established a worldwide sales network to prepare for its expected market launch of QRX003, as it advances clinical studies towards a...
90 Views
QNRX: Several Recent Milestones
The FDA recently granted QRX003 Orphan Drug Designation for the treatment of NS. The European Medicines Agency had granted Orphan Drug...
231 Views
QNRX: Recent FDA & EMA Designations for QRX003 Potentially Could Accelerate Timeline
The FDA recently granted QRX003 Rare Pediatric Disease (RPD) Designation for the treatment of NS. The European Medicines Agency earlier had...
197 Views
QNRX: With Clinical Activities Expanding, QNRX Expects Cash Runway Into 2Q26
In Dec. 2024, Quoin received FDA clearance to initiate a new investigator led whole-body clinical study for QRX003, which will evaluate the...
255 Views